Company Focus
Daiichi Sankyo
Latest Daiichi Sankyo News
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Daiichi Sankyo
Pharmaceutical
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread within the lungs or to other parts of the body. 21 June 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its June 2025 meeting. 20 June 2025
Pharmaceutical
Japanese drugmaker Mochida Pharmaceutical announced that Thien Thao Pharmaceutical Joint Stock Company, a partner of Meiji, has obtained approval to import and market Epadel S, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan, for the treatment of hypertriglyceridemia in Vietnam. 20 June 2025
Biotechnology
A report published by the Cell & Gene Collective, based on the findings of an expert commission, has offered recommendations to ensure the UK’s leadership in cell and gene therapies (CGTs) and urgently remove barriers to their adoption. 19 June 2025
Biotechnology
The US Food and Drug Administration has approved US biotech Incyte’s Monjuvi (tafasitamab-cxix) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL). 19 June 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese drugmaker Eisai and US biotech Biogen Leqembi (lecanemab) has not been recommended for use in the National Health Service (NHS) in England. 19 June 2025
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Pharmaceutical
US biopharma Mineralys Therapeutics has announced positive top-line data from its Phase II Explore-CKD trial evaluating the safety and efficacy of 25mg of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD). 18 June 2025
Latest In Brief for Daiichi Sankyo
Biosimilars
The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting. 20 June 2025
Latest Relevant Ones To Watch News
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze